Market Overview
Size, share, and layered assessment
- Brevintel analysis values the global TBI assessment market at USD 2.3 billion in 2025 ($2.3B), rising to USD 2.6 billion in 2026 and USD 4 billion by 2035 ($4B) at a 5.2% CAGR from 2026 to 2035.
- Philips led with over 15.1% market share in 2025; Philips, GE Healthcare, Siemens Healthineers, FUJIFILM, and RAUMEDIC collectively held about 45%.
- Assessment is moving from a CT-centered pathway toward a layered model: CT and MRI remain essential for acute hemorrhage, fractures, contusions, and diffuse injury.
- Biomarker assays, EEG-based systems, near-infrared hematoma detection, and eye-tracking tools can provide earlier risk stratification or extend assessment beyond imaging-equipped centers.
- Screening devices accounted for USD 1,876.8 million in 2025, or about 80.1% of market revenue, and are forecast to grow at a 5.0% CAGR.
- Monitoring devices generated USD 465.1 million but grow faster at a 6.1% CAGR as severe TBI management depends on continuous intracranial and cerebral oxygenation data.
- Hospitals remain the commercial center of gravity at USD 1,356.2 million in 2025, or about 57.9% of revenue, supported by ED, trauma, imaging, lab, and neurocritical-care capacity.
- North America contributed USD 940.2 million in 2025, while Asia Pacific, valued at USD 546.7 million, is forecast to expand at the fastest regional CAGR of 6.7%.
Clinical burden and pathway economics
- Demand rests on persistent clinical burden and the need to determine quickly which patients require imaging, intensive monitoring, or follow-up care.
- Global Burden of Disease data recorded 20.84 million incident cases and 37.93 million prevalent cases worldwide in 2021, with age-standardized incidence of 259 per 100,000 people.
- In the U.S., 214,110 TBI-related hospitalizations were reported in 2020, while 68,663 TBI-related deaths occurred in 2023.
- Global incident TBI cases increased by 53.3% between 1990 and 2021 even as age-standardized incidence declined, indicating population growth and aging expand absolute workload.
- Falls increasingly shape demand in aging economies, whereas road-traffic injuries remain central in lower- and middle-income settings.
- East Asia recorded 4.31 million TBI cases in 2021, with 69.85% classified as moderate or severe, elevating imaging and neurocritical monitoring relevance.
- A European study reported mean in-hospital costs of approximately €26,595, rising to €47,255 for patients receiving ICP monitoring.
- Brevintel analysis sees the 5.2% outlook as durable injury incidence tempered by workforce shortages, reimbursement uncertainty, and uneven high-acuity access.
Market Dynamics
Key drivers
- Adults aged 75 years and older accounted for approximately 32% of U.S. TBI-related hospitalizations, linking falls prevention, geriatric care, and emergency neuroimaging demand.
- Philips and SyntheticMR introduced Smart Quant Neuro 3D in February 2024, automating white-matter, grey-matter, CSF, and myelin segmentation with post-processing in under 10 seconds.
- bioMérieux received FDA 510(k) clearance for VIDAS TBI on May 1, 2024; the GFAP and UCH-L1 assay reports results in approximately 39 minutes on VIDAS 3 and VIDAS KUBE analyzers.
- Abbott’s assay for Alinity i and Architect i1000SR instruments reports results in 18 minutes, reinforcing laboratory-based triage for selected mild-TBI presentations.
- BrainScope’s Ahead 500 EEG-based platform may reduce head CT use by more than 30% in emergency-department deployment according to company reports.
- Nihon Kohden’s CerebAir wireless EEG headset reduces electrode application time from more than 30 minutes to approximately five minutes.
- InfraScan’s Infrascanner 2500 identifies certain intracranial hematomas in under three minutes; studies of 1,293 patients showed adult sensitivity of 92.5% and specificity of 82.9%.
- Oculogica’s EyeBOX provides a concussion-related score in under four minutes without a pre-injury baseline, supporting emergency, sports, and pediatric pathways.
Key restraints
- TBI assessment requires radiology interpretation, neurosurgical access for invasive monitoring, neurocritical-care management, and EEG review, so device availability does not equal utilization.
- The U.S. neurologist workforce was projected to face a shortfall of approximately 3,380 full-time equivalents by 2025, with demand of about 21,440 FTEs against supply of about 18,060.
- Non-metropolitan areas are projected to have neurologist adequacy equal to only 21.4% of demand by 2037, compared with 102% in metropolitan locations.
- Medicare patients wait an average of 34 days for an initial neurology consultation, and nearly one-fifth wait longer than three months.
- CT and MRI require capital investment, service support, staffing, and facility readiness; ICP and pBrO2 monitoring add procedure, ICU, and consumable costs.
- Integra re-launched CereLink in the first quarter of 2024 and reported high-single-digit neuro-monitoring growth in the fourth quarter of 2024, driven by CereLink.
- Cost barriers are most acute where injury burden is high but trauma infrastructure is thin, including import dependence and limited service networks.
- Brevintel analysis notes products that shorten setup, fit existing analyzers, and scale specialist expertise are better positioned than standalone technical features alone.
Segmentation Analysis
By product — screening devices
- Screening devices generate USD 1,876.8 million in 2025, representing approximately 80.1% of market revenue, and are forecast to grow at a 5.0% CAGR.
- CT scan represents USD 950.1 million in 2025 and is projected to grow at a 4.7% CAGR as the first-line modality for suspected acute TBI.
- Siemens’ SOMATOM On.Site mobile head CT demonstrated image quality approaching that of a conventional 64-slice stationary scanner in prospective comparison.
- Deep-learning denoising has enabled diagnostic neuroradiological trauma CT at approximately 25% of standard radiation dose in published research.
- FUJIFILM’s SCENARIA View combines 64-channel, 128-slice architecture with automated segmentation; GE HealthCare’s Revolution CT incorporates GSI Neuro dual-energy capability.
- MRI accounts for USD 853.4 million in 2025 and is estimated to grow at a 5.4% CAGR when CT does not explain persistent symptoms or diffuse axonal injury requires detail.
- Philips’ Smart Quant Neuro 3D offers automated tissue segmentation and myelin-volume mapping in under 10 seconds of post-processing.
- Other screening devices generate USD 73.4 million in 2025 and are forecast to grow at a 4.4% CAGR, spanning biomarkers, EEG triage, and portable neurodiagnostics.
By product — monitoring devices
- Monitoring devices generate USD 465.1 million in 2025 and are projected to grow at 6.1%, the fastest rate across product categories.
- ICP monitoring represents USD 403.2 million in 2025 and is forecast to expand at 6.3%, supporting osmotherapy, sedation, CSF drainage, and decompression decisions.
- RAUMEDIC’s NEUROVENT catheters are designed for parenchymal, ventricular, and epidural use, with options to measure ICP, intracranial temperature, and ptiO2 through a single insertion.
- pBrO2 monitoring generates USD 61.8 million in 2025 and is forecast to grow at 4.6%, supplying localized cerebral oxygenation that systemic saturation cannot provide.
- Natus Medical’s Moberg CNS Monitor integrates EEG, ICP, pBrO2, and other physiological inputs into a synchronized bedside environment.
- Adoption of pBrO2 remains more selective than ICP monitoring because it requires specialized protocols, interpretation expertise, and high-acuity care settings.
- Brevintel analysis sees faster monitoring growth as incremental clinical intensity after the first scan rather than displacement of structural imaging.
- Integrated catheters, monitoring platforms, and ICU workflow tools retain a defensible role where invasive access and specialist capability constrain utilization.
By end use
- Hospitals account for USD 1,356.2 million in 2025, or approximately 57.9% of market revenue, and are forecast to grow at 5.6%.
- Hospital purchasing spans CT, MRI, neurocritical monitoring, and laboratory biomarker analyzers because moderate and severe TBI concentrate in ED and trauma centers.
- Diagnostic centers generate USD 781.7 million in 2025 and are projected to grow at 4.9%, weighted toward follow-up imaging and post-concussive MRI assessment.
- Other end users account for USD 204.0 million in 2025 and are estimated to grow at 4.2%, including military, sports medicine, rehabilitation, urgent care, and EMS.
- InfraScan deployment in U.S. Marine Corps battalion aid stations illustrates NIR hematoma screening relevance in field care.
- ZOLL’s TBI Dashboard, cleared by the FDA in July 2021, trends SpO2, systolic blood pressure, and EtCO2 to support prevention of secondary brain injury during transport.
- Hospitals remain both the largest end-use segment and the most significant setting for recurring consumable demand.
- Brevintel analysis expects hospitals to remain the decisive commercial account for equipment placement, protocols, laboratory utilization, and patient volume.
Regional Outlook
North America and Europe
- North America generates USD 940.2 million in 2025, representing approximately 40.1% of global revenue, and is forecast to expand at a 4.3% CAGR.
- The U.S. contributes USD 881.6 million and is projected to grow at 4.2%, while Canada is forecast to grow at 6.4%.
- Comprehensive epidemiological analysis reported North America’s TBI incidence at approximately 1,299 cases per 100,000 population.
- Europe generates USD 664.1 million in 2025 and is projected to grow at a 4.9% CAGR, supported by imaging fleet replacement and standardized trauma protocols.
- The CENTER-TBI research network analyzed more than 4,000 admission CT scans from European trauma centers, supporting clinical standardization.
- VIDAS TBI had been CE-marked and deployed in selected European markets before U.S. clearance.
- A Spanish budget-impact analysis estimated annual savings of €696,634 for a hospital managing 3,500 mild-TBI patients after incorporating GFAP and UCH-L1 testing, or about €199 per patient versus CT-only protocols.
- Brevintel analysis contrasts North America’s revenue density with Europe’s health-economic case for biomarker pathway integration.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific generates USD 546.7 million in 2025 and is forecast to expand at 6.7%, the fastest regional rate.
- East Asia recorded the highest regional TBI case count in 2021 at 4.31 million cases, and 69.85% of cases in China were classified as moderate or severe.
- Abbott launched its laboratory-based blood test for mild TBI in India in June 2025, with availability at Apollo Hospitals and Neuberg Supratech Laboratory.
- Japan, South Korea, and Australia have more mature imaging systems and aging populations, supporting AI-enabled neuroimaging and fall-related injury assessment.
- Latin America generates USD 109.7 million in 2025 and is projected to grow at a 6.2% CAGR, concentrated in emergency and trauma settings.
- Middle East and Africa generates USD 81.2 million in 2025 and is forecast to grow at 5.7%.
- Saudi Arabia recorded an age-standardized TBI incidence of 681 per 100,000 population in 2021, among the highest national rates in global analysis.
- Regional revenue does not mirror incidence: North America’s about 40.1% share reflects trauma networks and reimbursement converting more presentations into formal diagnostics.
Competitive Landscape
Structure and company activity
- The market combines large imaging and monitoring suppliers with specialist companies serving discrete diagnostic gaps.
- Philips, GE HealthCare, Siemens Healthineers, FUJIFILM, and RAUMEDIC collectively account for approximately 45% of market share in CT, MRI, and invasive neuro-monitoring.
- bioMérieux participates through VIDAS TBI, cleared by the FDA in May 2024, with results in approximately 39 minutes on existing VIDAS analyzers.
- BrainScope offers FDA-cleared EEG-based assessment through the Ahead 500 platform without laboratory testing or invasive access.
- Integra LifeSciences competes in invasive neuro-monitoring through CereLink, re-launched in the first quarter of 2024 with enhanced accuracy and usability.
- Natus Medical offers BrainWatch point-of-care EEG and the Moberg CNS Monitor for synchronized neurocritical care.
- Nihon Kohden supplies CerebAir wireless EEG with approximately five-minute application time, while InfraScan and Oculogica address portable hematoma and concussion assessment.
- ZOLL Medical provides transport monitoring with TBI Dashboard functionality for EMS, military, and en-route care environments.
Integrated producers
- Philips
- GE Healthcare
- Siemens Healthineers
- FUJIFILM
- Integra LifeSciences
- Nihon Kohden
- ZOLL Medical
Specialty suppliers
- RAUMEDIC
- bioMérieux
- BrainScope
- Natus Medical
- InfraScan
- Oculogica
- Compumedics